ACCELERATE is the first ever natural history research study for Castleman disease patients! If you are a patient, we encourage you to get involved and power our research!
Patients (and family members of deceased patients) can enroll by clicking the button below! After you provide your name, phone number, and email, please check your email to finish registration. If you would prefer, you can also enroll into the study by telephone. Please call 215-349-5713 if you are interested. Loved ones of Castleman disease patients are not eligible to enroll into the study--We invite all loved ones of Castleman disease patients to join the CDCN community here.
Have you already participated in the ACCELERATE registration process?
If you have any additional questions, please email email@example.com or call 215-349-5713.
If you would like to speak to a ACCELERATE Patient Ambassador prior to registration, please contact Mileva at firstname.lastname@example.org or 412-860-8375.
To log back into the database, please click here.
If you are a Castleman disease physician anywhere in the world, please register here. For physicians treating Castleman disease patients involved in the ACCELERATE registry, please see ACCELERATE Physician Information.
What is the purpose of the ACCELERATE Registry?
ACCELERATE is the first-ever global patient registry of Castleman disease! It is designed to collect medical information and patient-reported information about Castleman disease.
As a collaborative partnership between the CDCN, Janssen Pharmaceuticals, and the University of Pennsylvania, ACCELERATE will be an observational, web-based registry that combines data from physicians and patients around the world to better understand this deadly disease and facilitate future research.
Who can participate?
ACCELERATE is a registry for patients with Castleman disease. If you are a patient or a family member of a deceased patient with Castleman disease, you may be eligible to participate. Participation will require a pathology report that suggests “Castleman disease.” Participation in ACCELERATE is entirely voluntary.